written on 12.05.2014
Tags:
,

Allergan board dismisses Valeant bid, but is it running out of options?

TAGS: ,

Allergan's board never seemed too thrilled with unsolicited $47 billion takeover proposal Valeant CEO J. Michael Pearson and partner Bill Ackman put forth last month.

Latest Report